E³ 432 - Prostate cancer: a multidisciplinary approach

1. To describe the potential clinical benefits of metastasis-directed therapies (MDT) for oligometastatic prostate cancer (OMPC) according to the castration state.
2. To learn how NGI alters OMPC states in prostate cancer and how the NGI modality/tracer affects the test accuracy.
3. To understand how test performance can affect the strategy of MDT including follow-up.
4. To realise the need for better evidence on the management impacts of NGI (inherent test inaccuracies, stage-migration, and survival biases).

1. To define the OMPC status in the prostate cancer landscape.
2. To understand the potential role of metastasis-directed therapies (MDT) in the different disease settings and describe available clinical evidence.
3. To provide insights on the future clinical directions of MDT strategies for OMPC.

1. To explore the currently available tools for targeted prostate cancer imaging and when they should be applied.
2. To learn if there is a role for bone scans for therapy selection.
3. To understand if there is a role for PSMA-targeted radiotherapy in oligometastatic patients.

1. To understand the fundamental importance of detecting a few more hot spots (the Pokemets concept).
2. To learn if there is data about the impact of PSMA PET on major clinical objectives.
3. To discuss if PSMA PET can be used to evaluate response to therapy.